We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

DNA Sequencing of Liquid Biopsy Specimens Increases Accuracy of Prostate Cancer Diagnosis

By LabMedica International staff writers
Posted on 12 Jan 2015
Print article
Life Technologies\' 5500xl SOLID next-generation DNA sequencer system
The 5500xl SOLID next-generation DNA sequencer system (Photo courtesy of Thermo Fisher (Life Technologies))
Next-generation sequencing analysis of DNA in the serum, a technique called liquid biopsy, can distinguish between prostate cancer patients, normal individuals, patients with benign hyperplasia, and those with noncancerous prostatitis.

Genomic instability resulting in copy number variation is characteristic of malignant transformation and may be identified through next-generation massive parallel sequencing. Tumor-specific cell free DNA (cfDNA) is released by dying cancer cells into the serum and plasma where it provides a real time, easily accessible target for this approach.

Investigators at Vanderbilt University (Nashville, TN USA) extracted DNA from serum of 204 patients with prostate cancer, 207 male controls, 10 patients with benign hyperplasia, and 10 with prostatitis. DNA was amplified by use of random primers, tagged with molecular identifiers, sequenced on a Life Technologies (Carlsbad, CA, USA) SOLID system, and aligned to the human genome.

Assessment of the results allowed the investigators to establish a model that discriminated prostate cancer from controls with an AUC (area under the curve) of 0.92 (0.87–0.95), reaching a diagnostic accuracy of 83%. Both benign prostatic hypertrophy and prostatitis could be distinguished from prostate cancer by use of cfDNA, with an accuracy of 90%.

"Based on the reported data and work in progress, I believe the "liquid biopsy" will revolutionize cancer diagnostics, not only before a patient begins therapy but also following patient responses to therapy," said contributing author Dr. William Mitchell, professor of pathology, microbiology, and immunology at Vanderbilt University. "Since cell-free DNA has a relatively short half-life in the circulation, sequencing of cell-free DNA soon after therapy may be used to detect minimal residual disease in solid tumors."

The study was published in the January 2015 issue of the journal Clinical Chemistry.

Related Links:

Vanderbilt University
Life Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.